Key result
KCNQ1 mutations increase L-type calcium current ~2-3-fold in JLNS, an effect shortened by diltiazem.
Why the study?
Pharmacologic block of I Ks produced minimal APD 90 increases whereas genetic loss of KCNQ1 markedly prolonged APD 90 , leaving the mechanisms underlying this prolongation undefined.
Does diltiazem improve action potential duration and QTc in Jervell and Lange-Nielsen syndrome models and patients?
Does diltiazem improve action potential duration and QTc in Jervell and Lange-Nielsen syndrome models and patients?
Answers are grounded in this paper and cite their sources.
Genetic loss of KCNQ1 in Jervell and Lange-Nielsen syndrome prolongs repolarization via down-regulation of calcium channel inhibitory genes and increased L-type calcium current, which can be targeted and shortened by diltiazem.
Background KCNQ1 loss of function variants are thought to cause type 1 long QT syndrome by reducing I Ks . However, we have recently reported that pharmacologic block of I Ks in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) produced minimal increases in action potential duration at 90% repolarization (APD 90 ), while genetic loss of KCNQ1 markedly prolonged APD 90 . We sought here to define mechanisms underlying APD prolongation by genetic loss of KCNQ1 . Methods We studied iPSC-CMs from population controls, an isogenic KCNQ1 knock out (KO) line created by a homozygous edit for the R518X loss of function variant, and 2 unrelated patients with the Jervell and Lange-Nielsen syndrome (JLN) due to compound heterozygosity for loss of function KCNQ1 variants. Results In both JLN and the KCNQ1-KO lines, I Ks was absent, APD 90 was markedly prolonged, and L-type Ca channel (LTCC) current ( I Ca-L ) was significantly increased, 2-3-fold, compared to the control cells with no change in kinetics or gating. RNA-sequencing identified 298 and 584 genes that were up– and down-regulated, respectively, by KCNQ1-KO compared to the isogenic control cells. Gene ontology analysis identified down-regulation of 6 Ca 2+ channel negative regulatory genes (p=0.0002, FDR=0.02), and in knockdown experiments in wild-type iPSC-CMs, three of these, CBARP , FKBP1B , and RRAD , increased I Ca-L , and RRAD increased APD 90 . A therapeutic low concentration (1 μM) of the Ca channel antagonist diltiazem significantly shortened APD 90 in the two JLN cell lines and in KCNQ1-KO cells. A single low dose of intravenous diltiazem in one of the JLN patients shortened QTc. Conclusions These data further support the concept that delayed repolarization in JLN cannot be explained solely by loss of I Ks . Our findings demonstrate that KCNQ1 mutations lead to down-regulation of Ca 2+ channel inhibitory genes, with resultant increased I Ca-L that underlies delayed repolarization in JLN. We further propose that diltiazem can be repurposed for treatment of patients with JLN.
No takes yet. Share an insight, caveat, or question.
Wada et al. (2025) studied Jervell and Lange-Nielsen syndrome. Diltiazem vs. Control cells was evaluated on L-type Ca channel (LTCC) current (ICa-L) and action potential duration at 90% repolarization (APD90) (2-3-fold increase in ICa-L, p=0.0002). KCNQ1 mutations in Jervell and Lange-Nielsen syndrome down-regulate calcium channel inhibitory genes, increasing L-type calcium current 2-3-fold, which can be shortened by diltiazem.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: